AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Freenome Appoints Rob Guigley as Chief Commercial Officer, Prepares for Commercial Launch of Cancer Tests.
ByAinvest
Monday, Nov 10, 2025 7:06 am ET1min read
Freenome has appointed industry veteran Rob Guigley as Chief Commercial Officer to drive commercial strategy. The appointment comes as the company's agreement with Exact Sciences clears antitrust review. Guigley will lead the execution of the exclusive U.S. licensing and commercialization of Freenome's colorectal cancer blood-based screening tests and build out the company's core commercial capabilities. The FDA is reviewing the Premarket Approval Application for the initial version of the test, with approval expected in H2 2026.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet